Conditions: Immune Thrombocytopenic Purpura
Keywords: Persistent Immune Thrombocytopenic Purpura Chronic Immune Thrombocytopenic Purpura
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 76
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).

Detailed description:

Arms:
arm 1: Subjects begin with Fostamatinib Disodium tablet 100 mg PO bid and increase to 150 mg big after week 4 based on platelet count and tolerability. arm 2: Placebo tablet PO bid (morning and evening) over the course of 24 weeks

Interventions: intervention 1: Fostamatinib disodium intervention 2: Placebo
Intervention descriptions: intervention 1: Fostamatinib (100 mg PO bid or 150 mg PO bid) intervention 2: Placebo tablet PO bid (morning and evening) over the course of 24 weeks

Protocol document: